If we want to understand where the next generation of products are coming from we have to dive deep beyond the obvious to ‘see’ where the field is going and why.

Sometimes this might involve clever strategies for hiding or masking the ability of the killer cells to ‘see’ normal cells in order to reduce on-target/off-tumour toxicities, other times we may need to use creative synthetic enhancements to give the product more robust performance in some other shape or form.

How should we go about achieving this next stage of nirvana? Can it be done, and if so, how, where, and what’s involved?

In this latest post, we take a look at what lies beyond and explain why some of the emerging ideas with cool targets might either make it through or fall at the cell therapy equivalent of Becher’s Brook at the Aintree Grand National…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by